Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 31NIH 5INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 1Glioblastoma 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Transurethral Resection of Bladder × Clear all
NCT06805305 2026-04-23

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Diakonos Oncology Corporation

Phase 2 Recruiting
180 enrolled
CNS

Glioblastoma

NCT07288112 2026-04-14

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Diakonos Oncology Corporation

Phase 1/2 Recruiting
35 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡